Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sun Yat-sen University
Weill Medical College of Cornell University
McGill University Health Centre/Research Institute of the McGill University Health Centre
Merck Sharp & Dohme LLC
BeOne Medicines
Bristol-Myers Squibb
Swiss Cancer Institute
Janssen Research & Development, LLC
AstraZeneca
Mirati Therapeutics Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Sun Yat-sen University
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
AstraZeneca
Bristol-Myers Squibb